Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

November 03, 2025 | Last Trade: US$3.53 0.68 -16.15

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Guggenheim Second Annual Healthcare Innovation Conference

Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Management will also participate in one-on-one meetings

Stifel 2025 Healthcare Conference

Presentation: Thursday, November 13, 2025, at 4:00 p.m. ET
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Management will also participate in one-on-one meetings

Jefferies 2025 London Healthcare Conference

Fireside Chat: Wednesday, November 19, 2025, at 10:30 a.m. GMT
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Management will also participate in one-on-one meetings

A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.

About Foghorn Therapeutics

Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.

Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$3.53
Daily Change:	-0.68 -16.15
Daily Volume:	1,048,814
Market Cap:	US$199.550M

October 30, 2025 Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs October 16, 2025 Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit August 05, 2025 Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update May 14, 2025 Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update May 01, 2025 Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors LOAD MORE NEWS

Featured Stock

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE